A study led by researchers at Ludwig Maximilians University Munich in Germany revealed a promising new biomarker linked to the lifespan control of important antibody-producing cells and relevant for autoimmune diseases like systemic lupus erythematosus (SLE). The study was recently published in the journal Nature Communications…
Systemic lupus erythematosus (SLE) treatments try to efficiently manage the disease while being safe and carrying a low rate of adverse events. Different strategies are currently used to control disease activity and prevent organ damage. To further understand if SLE is being adequately treated, a team of researchers lead by Dr. Christine Peschken looked at disease…
A new study recently published in the journal Nature Immunology revealed important insights into the generation of key cells of the immune system – dendritic cells. The study is entitled “Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common…
PharmaPoint, an industry leader in pharmacy management services, has published a report focused on lupus and its related therapeutic market, entitled “Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update.” Systemic lupus erythematosus (SLE) is an autoimmune disease in which the…
Lupus is a chronic disease for which there is currently no cure, with patients suffering with a lot of misconceptions and misunderstandings. Along with physicians, patients are the best people to discuss the disease, as is the case with Ellarea Maria Cole Stansbury, the author of the recently published book “…
Raanana, Israel based XTL Biopharmaceuticals Ltd. (XTL) has announced that following evaluation of market opportunity for its pipeline products its decision to focus efforts and expenditures exclusively on two core assets: hCDR1 for treatment of SLE/lupus and rHuEPO for “no-option” multiple myeloma patients. XTL, whose shares are traded on the…
A new study recently published in the journal Annals of the Rheumatic Diseases revealed the results of a Phase II trial assessing the use of the investigational therapeutic agent rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (SLE). The study was conducted by researchers at the…
A group of national bestselling authors gathered last Saturday to discuss the best ways to manage lupus at an event organized by the Lupus Foundation of America, Florida Chapter (LFAFL), which took place at the Nova Southeastern University, Orlando, Florida. The series of programs intended to improve knowledge on this autoimmune and…
A study led by researchers at the University of Michigan revealed that lupus nephritis can be linked to a specific DNA modification pattern in patients. The study was recently published in the Journal of Autoimmunity and is entitled “Renal involvement in lupus is…
The Lupus Foundation of America has recently launched the KNOW LUPUS campaign to raise awareness and funding to support patients with lupus, as well as research to cure the disease. The first positive result of the campaign was found during the filming of its public…